June 28, 2022 7:56am

Catalysts if any are not swaying investor sentiment; 2nd quarter reporting period is being prepared

Pre-open indications, 1 Negative Indications, 6 Positive Indications and 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are UP +0.66% (+208 points), S&P futures are UP +0.6% (+24 points) and NASDAQ futures are UP +0.56% (+67 points) early in the pre-open – so far,

 

Stock futures are on the rise on Tuesday for a positive open,

European stocks were slightly higher,

Asia-Pacific stocks were higher

 

Henry’omics:

On Monday, the Dow fell -62.42 points or -0.2%, the S&P 500 lost -11.63 points or -0.3% and the Nasdaq dropped -93.05 points or -0.7%.

“All three indexes are on course to notch two straight quarterly declines for the first time since 2015. They also appear set to post losses for June, which would mark three consecutive down months for the tech-heavy Nasdaq, its longest losing streak since 2015.” … Yahoo! finance>

Economic data surprised to the upside, with new orders for durable goods and pending home sales beating expectations.

Economic Data Docket: includes June consumer confidence and April home prices to gauge the health of the economy.

 

RegMed Investors’ (RMi) closing bell: “oversold as volatility ain’t over. Re-balancing and preparing for month and quarter’s end as earnings season returns – ug!” … https://www.regmedinvestors.com/articles/12490

 

Ebb and flow –

Q2/22 –

June – 9 positive and 9 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes

Q1/22:

·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative Indication:

uniQure NV (QURE) closed down -$0.44 to $18.67 with a negative -$0.66 or -3.54% pre-open indication,

 

Positive Indications:

Alnylam Pharmaceuticals (ALNY) closed down -$1.01 to $146.49 after Friday’s +$1.20, Thursday’s +$4.74, Wednesday’s +$2.54 and last Tuesday’s +$1.93 with a positive +$0.40 or +0.27% pre-open indication,

BioLife Solutions (BLFS) closed down -$0.80 to $14.92 with a positive +$0.79 or +5.29% pre-open indication.

Chinook Therapeutics (KDNY) closed +$0.67 to $18.72 with a positive +$0.28 or +1.50% pre-open indication,

Beam Therapeutics (BEAM) closed up again +$0.58 to $43.09 after Friday’s +$0.94 after Thursday’s -$2.44 with a positive +1.29 or +2.99% pre-open indication,

Global Blood Therapeutics (GBT) closed down -$2.04 to $29.75 with a positive +$0.51 or +1.71% pre-open indication,

CRISPR Therapeutics (CRSP) closed down -$0.06 to $66.90 after Friday’s +$1.81 <52-week low of $42.51> with a positive +$0.77 or +1.15% pre-open indication,

 

Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed $0.00 again after Friday’s flat to $4.30 with 0 shares traded, Thursday’s -$0.09 with 100 shares traded following Wednesday $0.00 and Tuesday’s +$0.09 with 467 shares traded.

WARNING:  Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors.

BSTG filed a new 8-K re Harvard BIOSCIENCE  (HBIO) and in lieu of cash payment < https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=116769338&type=HTML&formType=8-K&dateFiled=2022-06-13&cik=0001563665&CK=1563665&symbol=0001563665&companyName=Biostage >

BSTG seems to always finagling a finagle and NOTHING is CLEAN and STRAIGHTFORWARD.

 is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?

·         WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements

 

The BOTTOM LINE: U.S. equity futures traded higher Tuesday; potentially inciting more than a mild response to an oversold sector – a usual state of events.

There will be a few pick-up stocks – remember, the month and quarter are coming to a close – earnings are coming …

Investors may want to at least consider taking partial profits – when they can; we are approaching earnings season, no sooner did we finish than we start again.

I STILL haven’t heard the bugle sound of a sustainable advance or rally … rising rates and slowing economic growth are not a supportive environment for investors.

This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.

I have NOT seen ANY step-up of declining company investments by ANY CEOs and their management teams – WHY NOT?

I try to keep it simple … and short!

There is VALUE out there however, it’s about playing or betting the timing of the sector.

We are left with choosing to hang on to “our” portfolio position as it is a given that the sector shifts from fierce, sudden sell-offs to gaining altitude or ascending not to its value but, better than it was.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.